Fig. 3: Recommendations for the treatment of patients with relapsed and/or refractory multiple myeloma at third line and beyond. | Nature Reviews Clinical Oncology

Fig. 3: Recommendations for the treatment of patients with relapsed and/or refractory multiple myeloma at third line and beyond.

From: EHA–EMN Evidence-Based Guidelines for diagnosis, treatment and follow-up of patients with multiple myeloma

Fig. 3

Recommendations include supporting levels of evidence and have been graded170 (Supplementary Table 1). ADC, antibody–drug conjugate; Bela, belantamab mafodotin; CAR, chimeric antigen receptor; cilta-cel, ciltacabtagene autoleucel; d, dexamethasone; Dara, daratumumab; Elo, elotuzumab; ide-cel, idecabtagene vicleucel; Isa, isatuximab; K, carfilzomib; P, prednisone; Sel, Selinexor; V, bortezomib.

Back to article page